ZF-DELIVERY

ZF-Delivery

Coordinatore	UNIVERSITEIT LEIDEN    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	131˙926 €
EC contributo	131˙926 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2013-PoC
Funding Scheme	CSA-SA(POC)
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-03-01   -   2015-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITEIT LEIDEN  Organization address address: RAPENBURG 70 city: LEIDEN postcode: 2300 RA contact info Titolo: Mr. Nome: Ton Cognome: Brouwer Email: send email Telefono: +31 71 5273149	NL (LEIDEN)	hostInstitution	131˙926.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Within our ERC Starting Grant “Direct Drug Delivery”, we developed a method controlled fusion of liposomes and cells: a new pathway for direct drug delivery.

Our method of membrane fusion is inspired by natural occurring SNARE proteins, which control this process in-vivo. A set of complementary peptide amphiphiles were designed and these are able to induce the rapid and efficient fusion between two opposing membranes. In the ERC-project we have shown that our method of fusion can be applied to liposomes and to live cells. Since liposomes can be loaded with drugs, this enables the direct delivery of drugs into live cells.

We have recently found that our method also works in-vivo, which makes surface tagging and fusion applicable to zebrafish larvae. Drug screening and testing in Zebrafish larvae is becoming increasingly more popular as it reduces cost and enables rapid screening, making it easier to find new drugs. In this proposal, we want to investigate whether the market for applying our tagging and fusion of liposomes with zebrafish larvae enabling rapid in vivo drug screening is sufficiently large to make the commercialization of this method attractive for investors.'